Biotechnology Companies in Germany

Eurofins Genomics is a leading international provider of genomic services, specializing in next-generation sequencing, genotyping, and gene expression analysis. Based in Ebersberg, Germany, we support a diverse range of sectors including pharmaceuticals, diagnostics, agriculture, and research. As part of the Eurofins Scientific Group, a global life science leader with a presence in 61 countries, we leverage our extensive expertise and cutting-edge technology to deliver tailored genomic solutions. Our commitment to quality and precision, combined with our ISO 17025 accreditation, ensures reliable and impactful results for our clients worldwide. We offer a comprehensive portfolio of products and services, from custom oligonucleotide synthesis and gene synthesis to advanced sequencing and bioinformatics analysis, empowering scientific discovery and innovation.

We are a precision medicine pioneer in psychiatry based in Munich. Founded in 2010, our privately held biotech company combines the development of machine learning-enabled companion diagnostics with specific therapeutics to personalize the treatment of neuropsychiatric disorders with a focus on depression. Our ultimate goal is to improve the lives of patients by developing highly disruptive solutions for their high unmet medical needs. We strives to reduce not only the immense individual burden, but also the societal impact of these diseases. We develop patented genetic tests and combines those with innovative exclusively in-licensed medications, resulting in precise therapies for depression and other neuropsychiatric disorders.

WE ARE CREATING THE FUTURE OF HEALTH DISPENDIX provides premium liquid handling technology to scientists and lab technicians around the world, and is creating the future of medicine. Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany. In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 900+ colleagues and 11 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s award winning patented and widely recognized technology, the I.DOT (Immediate Drop-on-demand Technology), which brings intuitive automation, precision and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications.

Subitec is a solution provider covering its customers’ needs in leading edge industrial turnkey production plants and related supporting systems based on proprietary Flat Panel Airlift (FPA) photobioreactors-technology. More than twenty years ago Subitec started its activities with a strong focus on better understanding prerequisites and conditions of microalgae and cyanobacteria cultivation. Backed by this research know-how, Subitec nowadays has installed more than 50 production plants and supporting systems equipped with our proprietary FPA photobioreactors all over the world.

IRUBIS | Innovative Process Analytical Spectroscopy for Biomanufacturing. IRUBIS is a company that specializes in mid-infrared (MIR) spectroscopy for bioprocessing. We have designed an instrument, Monipa, specifically for bioprocess monitoring and control. Monipa is based on MIR spectroscopy, making it possible to monitor multiple bioprocesses real-time and continuously. Our instrument's applications are foreseen in both upstream and downstream bioprocessing. These include multiple metabolite monitoring and control in upstream processing. In addition, contaminant detection or monitoring of target proteins and excipients can be aided in downstream processing. Read more about our products and innovations at www.irubis.com.

Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

b.fab is specialized in the efficient conversion of CO2 and hydrogen (H2) from renewable energy into biotechnological value chains. CO2 and water are abundantly available and therefore it is our starting point to build a sustainable bioeconomy. We use formate as our central mediator to bind and store CO2 and H2 (made from water) in liquid form. Our bioprocesses start with the feedstock formate and we use Synthetic Biology to design specific pathways and to convert formate into value-added chemicals. Our platform is build on anaerobic and aerobic microbial production hosts to provide flexibility in the process design and adaptation to specific product requirements. We apply laboratory automation, high-throughput experimentation and advanced bioprocess development in an agile environment to develop new bioprocesses efficiently and in a minimal time frame. b.fab is dedicated to establish a Formate Bioeconomy in the coming years, and thus, providing an economical and sustainable new way to produce value-added chemicals for various industries.

Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients. The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders. With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.

Impulse Dynamics is dedicated to improving the lives of people with heart failure and is the developer of the innovative Optimizer®CCM® therapy delivery system. CCM® therapy is a breakthrough heart failure treatment that is proven to improve quality of life for heart failure patients. CCM® therapy is specifically designed to improve contraction of the heart in an effort to deliver more oxygen-rich blood to the body. CCM® therapy is a safe and effective minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them Optimizer was granted Breakthrough Device designation by the FDA and is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM® therapy. For important safety info visit: http://bit.ly/303mFRN

At LenioBio, we develop efficient, robust and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are. Unconstrained by the limitations of cells, we combine our proprietary protein technology with machine learning to significantly accelerate innovation cycles in life science industry.

Resolve Biosciences is applying the power of Molecular Cartography™ to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company's proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The platform offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program.

Cellbox Solutions is a young technology company focusing on delivering innovative and new solutions for the correct handling of living cells and biologic structures. Our product Cellbox is a self-sustaining carbon dioxide incubator supporting the appropriate storage, reproduction, transportation and analysis of biologic materials. The incubator’s temperature and gas environment can be adjusted based on the biosphere necessary for the cultivating cells stored.

Analytik Jena is a leading global supplier of analytical measurement technology in the field of molecular biology as well as liquid handling and automation technology. Whether in the fields of chemistry, pharmaceuticals, medicine and life science, food safety, agriculture or environmental analysis - Analytik Jena offers standard-compliant applications for routine analysis as well as for special tasks. Precision, reliability, easy handling and comprehensive service are the top priorities in the development of laboratory analysis products. Analytik Jena is part of the Swiss Endress+Hauser Group. Visit our YouTube profile for moving footage >>> https://www.youtube.com/@analytik-jena

Sqilline Health is transforming cancer care by turning complex clinical data into actionable evidence. Using large language models (LLMs) and AI-powered structuring, we unlock the full potential of oncology data — enabling better patient outcomes. We partner with life sciences and healthcare providers to accelerate research, improve outcomes, and ensure that no one faces cancer alone — not patients, nor physicians. At Sqilline Health, our mission is to bring clarity to cancer care. For more information, visit sqilline.com and follow us on LinkedIn.

For more than a decade the Tentamus Group has been providing services to customers all over the world. Our quality and safety services focus on the testing, auditing and consulting of products that influence human well-being from within. The Tentamus Group is valued by many companies as a true service partner for a wide range of products with a high degree of quality and local understanding. More than 90 laboratories with more than 4,000 highly qualified employees are part of the Tentamus Group worldwide. Regardless of the size of our group, we pride ourselves on providing tailor-made services to each of our customers, and we are honoured by their rapidly growing trust.

Ariceum Therapeutics is a private clinical-stage radiopharmaceutical company focused on the diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. Our lead targeted systemic radiopharmaceutical product, 177 Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours and childhood cancer, which currently has few treatment options and a poor prognosis. Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen. Headquartered in Berlin, Ariceum has operations in Germany and is active across Europe, North America and Australia.

KINOKO LABS is becoming BOSQUE FOODS ! We are excited to present our new brand and looking forward to showcase our first products soon. At Bosque Foods, we envision a world in which our future generations can prosper and thrive, without compromising the health of our planet. Our mission is to create better-than-meat products that deliver on the entire taste experience, nutrition, and price of traditional meat without compromise. Our solution is to create the best clean-image, minimally processed whole-cut meat and fish alternatives grown naturally from fungal mycelium.

By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. Our mission is to develop drugs that succeed and complement PARP inhibitors and facilitate the cure of therapy resistant cancers.

In Lignopure we produce natural degradable biopolymers from non-food sources. Our Lignopure product is the best-of-its-kind lignin, with proven non cytotoxicity and added functionality. No other lignin in the market can offer the safety of Lignopure and the tailored properties achieved through our protected technology. From the raw material production, we are able to deliver tailored lignin for different applications; these include particles for cosmetics, pharmaceuticals and food supplements. Additionally, our biobased prototypes include insulating materials, biobased polyurethane foams, aerogels and filaments for 3D printing. GO GREEN!

Pushing boundaries to drive Impact! Championing the future of protein through microorganisms Building Smaller, Better, Faster Hamburg & Lisbon Join us, we are hiring!

We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

traceless materials is a circular bioeconomy start-up offering a holistically sustainable alternative to plastics and bioplastics. With our first-of-a-kind biomaterial it’s our mission to contribute to solving global plastic pollution. Our innovative technology filed for patent allows to use food production residues to produce materials that are compostable under natural composting conditions. While bio-based, our materials don’t compete with food nor cause land-use-change, don’t need hazardous additives or solvents and have up to 87% lower CO2 emissions. Already competitive in quality, on industrial production scale they’ll be price competitive to virgin plastic in the EU. And since our materials are neither chemically modified nor synthetically polymerized, they will not fall under the EU Plastic Directive. Follow us on our journey, and become a part of the solution, not the pollution!

Start your journey to the future with our Complete Cryopreservation Program. Take your chance at a second life. At Tomorrow Biostasis we offer the complete cryopreservation program in Europe so you can potentially be revived in the future to live an extended life. Our focus is on advancement and education in the space of medical biostasis. As the fastest growing cryopreservation company in the world and with over 150 members, our aim is to build a world where people can choose how long they want to live. We are optimistic about the future, the development of technology, and - most importantly - life. Our team is young and driven, consisting of doctors, engineers, and entrepreneurs. Join us today, and get ready for tomorrow.

Die osteolabs GmbH ist eine Ausgründung aus dem GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel. Hier entstand die Idee, mit Hilfe von Spurenelementen im menschlichen Körper eine bisher nicht mögliche Früherkennung des individuellen Osteoporose-Risikos zu erreichen und darüber hinaus Therapieerfolge messbar zu machen. Meeresforscher des GEOMAR Helmholtz-Zentrums für Ozeanforschung Kiel haben gemeinsam mit Medizinern des Universitätsklinikums Schleswig-Holstein (UKSH) auf der Basis einer aus der Meeresforschung stammenden Analysemethode ein Früherkennungsverfahren für Veränderungen in der Knochencalciumbilanz entwickelt, das eine frühestmögliche Aussage erlaubt. „Wir verwenden eine Analysemethode für Calciumisotope, die nur Urin oder Blut für die Untersuchung benötigt“, so Prof. Dr. Anton Eisenhauer, Meeresforscher und wissenschaftlicher Leiter der osteolabs GmbH. Der Ansatz stieß von Anfang an auf hohes Interesse und wurde von mehreren öffentlichen und privaten Institutionen gefördert.

Herstellung und Vertrieb effektiver und sicherer Reiniger für Mensch, Tier und Natur auf Basis natürlicher Rohstoffe. Spezialisiert auf die Entwicklung von Reinigern zur Entfernung von Öl- und Fettverunreinigung insbesondere Ölspuren/Ölfilmen auf öffentlichen Verkehrsflächen.

Sartorius is a leading international partner of life sciences research and biopharmaceutical manufacturing. We help our customers #SimplifyProgress from drug discovery to manufacturing so that more people can have access to better medicine. With this, we are #PartOfTheSolution in the fight against diseases worldwide. With innovative laboratory instruments and consumables, the our Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. Based in Göttingen, Germany, Sartorius also has a strong global reach with around 60 production and sales sites worldwide. We regularly expand our portfolio through the acquisition of complementary technologies. In 2023, Sartorius generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees from around 110 nations are working for customers around the globe. Join our team, partner or collaborate with us.

GBA Group is an international life science services company with over 3,000 employees and a wide range of analytical, logistical and specialist services in the fields of pharmaceuticals, medical devices, cosmetics, chemicals, food, drinking water and the environment. The group stands for outstanding technical expertise, efficient processes and full focus on customer benefits with regard to its activities in the fields of research, product development, market development and consumer protection. With its services, GBA Group directly and indirectly makes a sustainable contribution to health, the environment and society.

Building the Collective Digital Immune System for Longevity We use decentralized artificial intelligence to build a framework for applications to search, discover, and compute on personal omics and biomarker data. By leveraging machine learning, advanced cryptography, and autonomous agents based on a privacy-preserving Identity infrastructure, our blockchain-mediated collective learning system enables individuals and multiple stakeholders in the health sector to build a shared machine learning model without needing to rely on a central authority, and without revealing any datasets to other stakeholders. The NOMIX team consists of curious experts in the fields of AI/ML, blockchain technology, cryptography, bioinformatics, bioengineering, and company building. Our work is based on the core principles of eco-responsibility, sustainability, transparency, regulatory compliance, scalability, and reliability.

Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases. At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates, called TPCs (Topas Particle Conjugates) uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner. TPCs are uniquely engineered to restore and promote immune tolerance by targeting liver sinusoidal endothelial cells (LSECs) and harnessing antigen-specific immune tolerance mechanisms of the liver. Our technology has delivered to date two clinical candidates: TPM203 (Phase 1 pemphigus vulgaris) and TPM 502 (Phase 2 celiac disease).

Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.